DrugBank

JUNE 6, 2024

In the rapidly evolving landscape of oncology drug development, artificial intelligence (AI) has emerged as a revolutionary force, altering not just the pace but the very methodology of discovery and development.

Drug Development 74

Drug Development Clinical Trials Drugs Therapies 74

Drug Discovery World

SEPTEMBER 6, 2022

In recent years the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are not only transforming the way diseases are treated but are also aiming to cure entirely new patient populations. Record breaking investments in 2021 fuel an industry on fire . billion raised.

Therapies 130

Therapies Clinical Trials Production Disease 130

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. Historically, what has limited investor interest in funding neurological and psychiatric therapies in development?

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Discovery World

FEBRUARY 12, 2024

Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery. It’s no surprise that interest in AI for this area is surging, since early phase drug discovery normally accounts for 42% of the cost of the entire pipeline.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Drug Discovery World

JULY 17, 2023

Analysis of 13,490 clinical trials finds almost a third have been cancelled during Phase II amidst an overall decline in clinical development productivity. Data analytics company Phesi has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date.

Clinical Trials 130

Clinical Trials Trials Clinical Development Therapies 130

Drug Discovery World

SEPTEMBER 12, 2022

If anything, this period has been a reminder that people are the primary reason we do what we do, and the Patient Access, Healthcare & People track at Advanced Therapies Europe 2022 allowed DDW’s Multimedia Editor Megan Thomas to share several reflections on the topic. .

Clinical Trials 130

Clinical Trials Trials Therapies Science 130

Conversations in Drug Development Trends

DECEMBER 7, 2023

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture. We are acutely aware that turnover in key project team personnel can lengthen project timelines and inflate clinical trial costs.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

Drug Discovery World

NOVEMBER 21, 2023

Treehill has designed its model to fully utilise its expertise representing buy- and sell-side clients across therapeutic areas and all stages of development.

Clinical Development 130

Clinical Development Production Marketing Drug Development 130

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Clinical Trials 130

Clinical Trials Immune Response Trials Drugs 130

FDA Law Blog: Drug Discovery

NOVEMBER 2, 2023

Lewis, Senior Regulatory Device & Biologics Expert — On October 20, 2023, FDA announced the availability of the final guidance authored by CBER titled “Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies.” It finalized a draft guidance published in 2022.

Therapies 59

Therapies FDA Production Regulations 59

Drug Discovery World

JULY 15, 2024

Dr Alexandra Sapetschnig, Group Leader at STORM Therapeutics, described the event as one that “really set the agenda for oncology research in 2024” through the display of new approaches and methods that are expanding opportunities in drug development. This bodes well for potential future research and therapies,” she adds.

Research 130

Research Clinical Pharmacology Therapies RNA 130

Cytel

SEPTEMBER 1, 2023

Data is the cornerstone of any clinical trial, driving the decision-making process of drug development, and is a fundamental requirement for approval of new therapies by regulatory agencies like the FDA or EMA.

Clinical Development 64

Clinical Development Clinical Trials FDA Drug Development 64

PPD

MARCH 26, 2024

A large majority of drug developers utilize FSP or hybrid FSP/FSO models, half are “heavy users” Heavy users: Those that use FSP or hybrid FSP/FSO models for most of their clinical development outsourcing. Heavy users leverage these models for nearly three-quarters of their outsourcing.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Research Clinical Development Drug Development 98

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and contr­­ols (CMC).

Therapies 59

Therapies Engineering Production FDA 59

Drug Discovery World

JUNE 29, 2023

It’s been another busy month for senior appointments in the drug discovery sector. David Favre, Chief Development Officer, SpliceBio Dr Favre brings more than 25 years of experience in gene therapy, immunology and drug development throughout academia and the biopharma industry.

Drugs 130

Drugs Laboratories Research Laboratories Clinical Trials 130

Drug Discovery World

SEPTEMBER 14, 2023

Evaluating Immatics’ IMA203 TCR-T therapy, targeting PRAME, in combination with Moderna’s PRAME mRNA-based cancer vaccine. Moderna will lead the clinical development and commercialisation of cancer vaccines and TCER therapeutics resulting from the collaboration.

Vaccine 130

Vaccine Bioinformatics Clinical Trials Therapies 130

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding. Northern Ireland “Northern Ireland is a medtech super-hub,” says Saleko.

Drugs 190

Drugs Science Therapies Targeted Protein Degradation 190

Drug Discovery World

DECEMBER 27, 2023

Ng is working on critical challenges in clinical trials, specifically in planning and recruitment, and has been building innovative solutions designed to benefit patients and researchers – with a focus on efficiency, transparency and diversity in clinical development. Listen here. Listen here. Listen here.

Targeted Protein Degradation 174

Targeted Protein Degradation Clinical Trials Pharma Companies Drug Development 174

Agency IQ

FEBRUARY 12, 2024

BY RACHEL COE, MSC | FEB 7, 2024 10:21 PM CST The Bespoke Gene Therapy Consortium A collaborative effort, the Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021 to “accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.”

FDA 40

FDA Therapies Clinical Trials Virus 40

Drug Discovery World

APRIL 6, 2023

Granular Therapeutics, a UK-based biotech company specialising in precision biologic therapies for treating mast cell driven disorders, announced clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies.

Disease 130

Disease Clinical Development Therapies Drugs 130

Drug Discovery World

MAY 3, 2023

” The post Successful financing ensures development of Adcendo’s ADC asset appeared first on Drug Discovery World (DDW). The expression profile and internalising properties of uPARAP make it an attractive ADC target.

Licensing 130

Licensing Licensing Clinical Development Therapies 130

Drug Discovery World

MARCH 14, 2023

The funding will allow us to take our first-in-class, lead drug candidate, TT-P34 from candidate selection into clinical development, while also advancing our novel pipeline of innovative peptides.

Disease 130

Disease Treatment Science Clinical Development 130

Drug Discovery World

MAY 6, 2024

Even before this, however, Amsterdam was established as an important centre for drug development. The company is now investigating a promising gene therapy for Huntingdon’s disease in a Phase I/II trial, with patients already showing signs of preserved neurological function. The CDD will sponsor and manage KWF-supported trials.

Drugs 148

Drugs Science Molecular Biology Clinical Trials 148

Drug Target Review

FEBRUARY 29, 2024

Through further research and work as a principal investigator on clinical studies for several central nervous system indications, I laid the groundwork for a career in gene therapy drug development. AskBio) I continue to work to bring innovative gene therapies to patients in need.

Therapies 111

Therapies Disease Clinical Trials Science 111

The Pharma Data

JANUARY 12, 2021

In December, life sciences giant Bayer launched a cell and gene therapy platform within its pharmaceutical division in order to become a leading company within a rapidly emerging and evolving field that offers the potential of life-saving therapies. Photo courtesy of Bayer. We have set the bar high.

Therapies 52

Therapies Licensing Licensing Pharmaceuticals 52

Drug Discovery World

OCTOBER 4, 2022

“Recent reports suggest global market value is forecasted to grow to $25-$40 billion before the end of this decade, driven primarily by the introduction of disease-modifying therapies with accompanying biomarkers for early diagnosis, coupled with the demographic rise in the number of patients.” . William Erhardt, M.D.,

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Conversations in Drug Development Trends

JANUARY 24, 2024

Why Partnering with Genetic Counselors May Benefit Your Clinical Program The American College of Medical Genetics (ACMG) has issued a statement that geneticists should be involved in the development of genetic therapies. Enrolling adequate populations will be required to advance these programs.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Drug Target Review

MAY 7, 2024

Small patient populations often result in difficulty in determining a significant effect of a therapy, given the low confidence power associated with the statistics. How do AI-enhanced approaches accelerate the drug development process for rare diseases?

Disease 59

Disease Clinical Trials Clinical Pharmacology Trials 59

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim is pioneering a range of versatile therapeutic platforms in order to develop innovative medicines that target the tumor directly (tumor cell-directed therapies) or that enable the immune system to target the tumor (immune cell-targeted therapies). About Boehringer Ingelheim.

Licensing 52

Licensing Licensing Therapies Science 52

Drug Discovery World

FEBRUARY 10, 2023

The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA. The post This week in drug discovery (6-10 February) appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

FDA Law Blog: Drug Discovery

JUNE 12, 2024

The START pilot program was announced last September as a way to offer selected participants developing potentially life-saving and life-changing rare disease therapies enhanced communications with FDA review staff and a mechanism for addressing clinical development issues, similar to the “Operation Warp Speed” communication model for vaccines in development (..)

Disease 59

Disease Clinical Trials FDA Clinical Development 59

Drug Discovery World

JUNE 1, 2023

In May 2023, Japanese drug-maker Eisai entered into a joint development agreement with Chinese drug-developer Bliss Biopharmaceutical for BB-1701, an ADC with option rights for a strategic collaboration 6. This appears to be supported by the number of Chinese collaborations, approvals and expansions in 2023 alone.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

KIF1A

SEPTEMBER 30, 2023

Read the Guide FDA Launches Pilot Program to Help Further Accelerate Development of Rare Disease Therapies One frustrating aspect of traditional drug development, especially for rare disease communities, is the tempo of regulatory decisions on potential drugs.

FDA 111

FDA Disease Clinical Trials Therapies 111

LifeSciVC

JULY 11, 2023

Redig, SVP and Head of Clinical Development at HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The American Cancer Society for Oncology (ASCO) annual meeting is among the highlights of the clinical oncology calendar. By Amanda J.

Therapies 67

Therapies Trials Clinical Development Science 67

Drug Target Review

JANUARY 8, 2024

Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases.

Science 145

Science Disease FDA Approval Pharmaceutical Companies 145

Vial

MARCH 25, 2024

In the past three years, Worldwide has collaborated on 105 oncology studies supported by a global team of oncology clinical development experts. Other therapeutic areas include cell and gene therapy. Clinical trial designs are expected to become more complex, generating more data volume and diversity.

Clinical Trials 52

Clinical Trials Trials Clinical Development Clinical Research 52